SP1

Transcription factor Sp1 · P08047 · SP1 on Sugi Atlas →

57 patent compounds predicted against SP1, 36 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sepantronium (SCHEMBL727997)	1.00	1/20
Sepantronium (SCHEMBL29493286)	1.00	1/20
Sepantronium (SCHEMBL2814447)	0.98	1/20
Sepantronium (SCHEMBL2814857)	0.98	1/20
Bromide (SCHEMBL15062823)	0.79	1/20
SCHEMBL6190071	0.74	1/20
Sepantronium (SCHEMBL16584072)	0.73	1/20
Sepantronium (SCHEMBL29379252)	0.73	1/20
SCHEMBL6190207	0.72	1/20
Sepantronium (SCHEMBL6188375)	0.71	1/20
Sepantronium (SCHEMBL29464041)	0.71	1/20
SCHEMBL21614164	0.70	1/20
Hydrochloric Acid (SCHEMBL6188651)	0.69	1/20
SCHEMBL6188546	0.64	1/20
Bromide (SCHEMBL22413046)	0.61	1/20
SCHEMBL26354926	0.59	1/20
SCHEMBL6187056	0.58	1/20
SCHEMBL6189812	0.57	1/20
SCHEMBL6191935	0.57	1/20
SCHEMBL6189328	0.55	1/20

Clinical trials — most relevant to SP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Effects of Repetitive Transcranial Magnetic Stimulation in the Treatment of Phantom Limb Pain in Landmine Victims: ANTARES	PHASE3	COMPLETED
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer	PHASE1/PHASE2	COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.	PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Simvastatin in Secondary Progressive Multiple Sclerosis	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)	PHASE2	RECRUITING
Acupuncture to Reduce Signs of Inflammation in Participants With Chronic Low Back Pain	PHASE1	COMPLETED
Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study	EARLY_PHASE1	COMPLETED
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism	EARLY_PHASE1	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?	nan	UNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis	nan	COMPLETED
Family Resilience Initiative Research Program	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Immune Interactions in Severe Asthma	nan	COMPLETED
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)	nan	COMPLETED
Hypoxia Inducible factor1-Alpha Genetic Polymorphism of Obstructive Sleep Apnea	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SP1 binder may also engage these)

Protein	Name	Similarity
O89090	—	1.000	O89090 →
Q01714	—	1.000	Q01714 →
Q62445	—	0.997	Q62445 →
Q02446	—	0.992	Q02446 →
Q5E9U0	—	0.989	Q5E9U0 →
Q9D2H6	—	0.988	Q9D2H6 →
Q90WR8	—	0.988	Q90WR8 →
Q01147	—	0.987	Q01147 →
Q02447	—	0.987	Q02447 →
CREB1	Cyclic AMP-responsive element-binding protein 1	0.987	landscape →
Q29076	—	0.987	Q29076 →
P25425	—	0.986	P25425 →
Q86NP2	—	0.986	Q86NP2 →
O70494	—	0.985	O70494 →
P78364	—	0.985	P78364 →
P27925	—	0.984	P27925 →
P16143	—	0.984	P16143 →
P15143	—	0.984	P15143 →
Q1LZH5	—	0.983	Q1LZH5 →
Q9JM73	—	0.983	Q9JM73 →
Q08DA8	—	0.983	Q08DA8 →
Q5E9S2	—	0.983	Q5E9S2 →
Q64028	—	0.983	Q64028 →
P15337	—	0.983	P15337 →
P13002	—	0.982	P13002 →
P18576	—	0.982	P18576 →
Q03061	—	0.982	Q03061 →
Q4VYS1	—	0.982	Q4VYS1 →
Q02086	—	0.981	Q02086 →
P79145	—	0.981	P79145 →